Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. The company is headquartered in Marlborough, Massachusetts and currently employs 53,000 full-time employees. The firm's MedSurg segment includes Endoscopy, Urology, and Neuromodulation. Its Endoscopy business develops and manufactures devices to diagnose and treat a range of gastrointestinal conditions with less-invasive technologies. Its Urology business develops and manufactures devices to treat various urological conditions for both male and female anatomies, including kidney stones, benign prostatic hyperplasia, prostate cancer, erectile dysfunction, and incontinence. Its Neuromodulation business develops and manufactures devices to treat various neurological movement disorders and manage chronic pain. Its Cardiovascular segment includes Cardiology and Peripheral Interventions. The Cardiology includes interventional cardiology therapies, watchman, cardiac rhythm management, and electrophysiology.
Follow-Up Questions
What is Boston Scientific Corp (BSX)'s P/E Ratio?
The P/E ratio of Boston Scientific Corp is 76.2934
Who is the CEO of Boston Scientific Corp?
Mr. Michael Mahoney is the Chairman of the Board of Boston Scientific Corp, joining the firm since 2011.
What is the price performance of BSX stock?
The current price of BSX is $98.1, it has decreased 0.73% in the last trading day.
What are the primary business themes or industries for Boston Scientific Corp?
Boston Scientific Corp belongs to Health Care industry and the sector is Health Care
What is Boston Scientific Corp market cap?
Boston Scientific Corp's current market cap is $145.3B
Is Boston Scientific Corp a buy, sell, or hold?
According to wall street analysts, 35 analysts have made analyst ratings for Boston Scientific Corp, including 14 strong buy, 22 buy, 4 hold, 0 sell, and 14 strong sell
